In this photo illustration, boxes of the diabetes drug Ozempic rest on a pharmacy counter on April 17, 2023 in Los Angeles, California.
But it could potentially include Eli Lilly 's diabetes drug Mounjaro, which is approved in the EU.
Liraglutide is the active ingredient in Novo Nordisk's weight loss drug Saxenda.
Semaglutide is the active ingredient in the Danish company's weight loss injection, Wegovy, and its diabetes counterpart, Ozempic.
They mimic a hormone produced in the gut called GLP-1 to suppress a person's appetite and ultimately aid with weight loss.
Persons:
Eli Lilly, It's, Liraglutide, Semaglutide, ideation
Organizations:
Novo Nordisk, European Medicines Agency, Pfizer, EMA, CNBC, Icelandic Medicines Agency, Novo Nordisk's Saxenda, Food and Drug Administration
Locations:
Los Angeles , California, Danish, Wegovy's, U.S